Last updated on September 2017

Randomized Study of CX-01 Combined With Standard Induction Therapy for Newly Diagnosed Acute Myeloid Leukemia


Brief description of study

The purpose of this study is to determine whether CX-01 when given together with standard induction and consolidation therapy for acute myeloid leukemia (AML) will increase the effectiveness of the induction/consolidation therapy. Three different doses of CX-01 will be studied and safety and tolerability will be assessed.

Detailed Study Description

This randomized open-label study is designed to evaluate whether the addition of either or all 3 different dose levels of CX-01 to standard induction therapy and consolidation therapy and has a beneficial effect in newly diagnosed AML patients (60 years of age or older) when compared to patients receiving standard induction and consolidation chemotherapy alone. 160 patients will be randomized one of 4 treatment groups to receive standard induction/consolidation therapy alone or standard induction/consolidation therapy with CX-01 at one of 3 different dose levels (low, medium and high). Patients will receive up to 2 induction cycles and up to 3 consolidation cycles and will participate in the study for up to 18 months. Clinical laboratory tests will be conducted routinely, and bone marrow aspirates and biopsies will be performed during the induction cycles. Safety will be monitored through adverse events and clinical laboratory results.

Clinical Study Identifier: NCT02873338

.

Contact Investigators or Research Sites near you

Start Over

Please choose location

View all locations

Matthew Wieduwilt, MD

University of California, San Diego, Moores Cancer Center
La Jolla, CA United States
  Connect »

Michael Maris, MD

Colorado Blood Cancer Institute
Denver, CO United States
  Connect »

Imaduddin Tabbarah, MD

George Washington University
Washington, D.C., United States
  Connect »

Stephen E Rubenstein, MD

Franciscan St. Francis Health
Indianapolis, IN United States
  Connect »

Donald B Wender, MD

June E. Nylen Cancer Center
Sioux City, IA United States
  Connect »

Don Stevens, MD

Norton Cancer Institute
Louisville, KY United States
  Connect »

Hana Safah, MD

Tulane University/Tulane Cancer Center
New Orleans, LA United States
  Connect »

Jay Yang, MD

Karmanos Cancer Institute
Detroit, MI United States
  Connect »

Michaela Tsai, MD

Allina Health - Virginia Piper Cancer Institute
Minneapolis, MN United States
  Connect »

Peter Westervelt, MD

Washington University School of Medicine in St. Louis
Saint Louis, MO United States
  Connect »

Cecilia Arana-Yi, MD

New Mexico Cancer Care Alliance
Albuquerque, NM United States
  Connect »

Jonathan Kolitz, MD

Northwell Health, Monter Cancer Center
Lake Success, NY United States
  Connect »

Ioannis Mantzaris, MD

Montefiore Medical Center
The Bronx, NY United States
  Connect »

Zartash Gul, MD

University of Cincinnati
Cincinnati, OH United States
  Connect »

Rachel Cook, MD

Oregon Health & Science University Knight Cancer Institute
Portland, OR United States
  Connect »

John Reagan, MD

Rhode Island Hospital
Providence, RI United States
  Connect »

Robert Stuart, MD

Medical University of South Carolina
Charleston, SC United States
  Connect »

Vinod Parameswaran, MD

Avera Cancer Institute
Sioux Falls, SD United States
  Connect »

William B Donnellan, MD

Tennessee Oncology/Sarah Cannon Research Institute
Nashville, TN United States
  Connect »

Moshe Levy, MD

Baylor Research Institute/Baylor Sammons Cancer Center/Baylor University Medical Center
Dallas, TX United States
  Connect »

Jose C Cruz, MD

Methodist Healthcare System of San Antonio
San Antonio, TX United States
  Connect »

Paul Shami, MD

Huntsman Cancer Institute
Salt Lake City, UT United States
  Connect »

Daanish Hoda, MD

LDS Hospital
Salt Lake City, UT United States
  Connect »

Raya Mawad, MD

Swedish Cancer Institute
Seattle, WA United States
  Connect »